No Data
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Assessing Warby Parker: Insights From 5 Financial Analysts
Warby Parker (NYSE:WRBY) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a snapshot of their recent
Express News | UBS Maintains Neutral on Warby Parker, Raises Price Target to $15
Warby Parker Guidance Achievable, Path Still Uncertain, Morgan Stanley Says
Warby Parker (WRBY) could deliver its guidance for Q2 and the full-year but its expectation for selling, general, and administrative expenses, or SG&A, trajectory may be too optimistic, Morgan Stanley
Warby Parker Q1 2024 Earnings: Revenue Surges, Beats Estimates
Warby Parker Is Maintained at Equal-Weight by Morgan Stanley
Warby Parker Is Maintained at Equal-Weight by Morgan Stanley